● pepmg Research Desk · Peer-reviewed evidence review
What the research says about adipotide
A neutral summary of the peer-reviewed literature on adipotide, a fat-targeting pro-apoptotic peptidomimetic studied in obese monkeys and rodent models. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Adipotide is an experimental pro-apoptotic peptidomimetic designed to target the blood-vessel lining of white fat and trigger its programmed cell death [1].
- The evidence is preclinical: the best-known study was in obese monkeys, where adipotide induced weight loss and improved insulin resistance but also produced dose-related, reversible changes in kidney (renal proximal tubule) function [1].
- There are no controlled human trials of adipotide, and a published commentary questioned whether the weight loss reflected a direct fat-targeting effect or simply reduced food intake [3].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What adipotide is
Adipotide is described in the literature as a ligand-directed peptidomimetic (sequence CKGGRAKDC linked to a pro-apoptotic KLAKLAK motif) engineered to home to prohibitin, a marker on the blood vessels that supply white adipose tissue, and to induce apoptosis (programmed cell death) in those vessels [1]. The intent was to shrink fat by cutting off its blood supply rather than by acting on appetite directly [1].
It is sold as a research chemical. This page summarizes the published preclinical research; material from third-party vendors is offered for laboratory and research use only and is not a medicine for any condition.
What the preclinical research has measured
Preclinical onlyThe landmark study tested adipotide in obese Old World monkeys (primates), a model chosen because rodent-to-primate differences complicate translating anti-obesity strategies [1]. Treatment induced targeted apoptosis within the blood vessels of white adipose tissue and resulted in rapid weight loss and improved insulin resistance, with magnetic-resonance imaging and dual-energy x-ray absorptiometry confirming a marked reduction in white adipose tissue [1].
The broader concept has also been explored in rodents. A study in diet-induced-obese mice reported that a prohibitin-targeted nanoparticle carrying the same pro-apoptotic peptide reduced body weight and improved dysfunctional fat tissue, framed as a comparison against the adipotide bioconjugate [2].
There are no controlled human trials in this evidence base. A commentary on the primate study argued that the observed weight loss might partly reflect a direct effect of adipotide on food consumption rather than its intended vascular-targeting mechanism, underscoring that the mechanism in vivo is not fully settled [3].
What the studies report on safety and adverse events
Preclinical onlyThe primate study measured organ effects alongside weight loss. At the experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal-tubule function, a kidney-related signal the authors highlighted as a defining feature of this drug class [1].
Because the evidence is preclinical, there is no controlled human safety dataset for adipotide. The kidney finding in primates and the mechanism (deliberately inducing cell death in the vasculature of a tissue) are the salient cautionary observations in the published work [1].
No human safety conclusions can be drawn from this evidence base. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence is characterized as preclinical: adipotide has been studied in obese monkeys and rodent models, with no controlled human trials, and even the primate mechanism has been questioned in the literature [1][3]. "Preclinical" describes where the research sits, not a verdict that adipotide does or does not work, and the kidney effects seen in primates are a notable reason for caution.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 3
- A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.
- A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.
- Comment on "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.